Cancer Family
Digestive System Neoplasm
CI-CAN-00000012Explore in graph →
Non-malignant4,733 active trials43 approved drugs557 evidence items
Loading cancer entity…
Cancer Family
CI-CAN-00000012Explore in graph →
Clinical trials
22,059 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06487221 | Avutometinib and Defactinib in Diffuse Gastric Cancer | recruiting | Phase 2 | 27 | Ryan H. Moy, MD, PhDOTHER | 1 | Nov 4, 2025 | clinicaltrials |
| NCT07212933 | The Safety and Clinical Efficacy of RAK Cell Therapy in Late-stage Gastric Cancer: A Randomized Controlled Trial(RAK in GC) | recruiting | Phase 2 | 90 | Chinese PLA General HospitalOTHER | 1 | Oct 8, 2025 | clinicaltrials |
| NCT06789757 | The Study of Atezolizumab, Bevacizumab and Memantine in Patients With Hepatocellular Carcinoma (HCC)((HCC)) | recruiting | Phase 2 | 19 | Inova Health Care ServicesOTHER | 1 | Oct 7, 2025 | clinicaltrials |
| NCT05377034 | Multinational Phase II Trial to Compare Safety and Efficacy of SIRT (Y-90 Resin Microspheres) Followed by Atezolizumab Plus Bevacizumab, vs SIRT (SIRT-Y90) Followed by Placebo in Locally Advanced HCC Patients(STRATUM) | recruiting | Phase 2 | 100 | National Cancer Centre, SingaporeOTHER | 4 | Oct 6, 2025 | clinicaltrials |
| NCT00722228 | Autologous and Allogeneic Whole Cell Cancer Vaccine for Metastatic Tumors | recruiting | Phase 1 / Phase 2 | 50 | Hadassah Medical OrganizationOTHER | 1 | Oct 2, 2025 | clinicaltrials |
| NCT03492671 | Testing the Combination of Two Approved Chemotherapy Drugs and Radiation Prior to Surgery in Localized Pancreatic Cancer | recruiting | Phase 2 | 30 | Loma Linda UniversityOTHER | 1 | Oct 2, 2025 | clinicaltrials |
| NCT05040815 | Inguinal Node Sparing Radiotherapy For Patients With Early Stage Anal Cancer(INSPIRE) | recruiting | Phase 2 | 45 | AHS Cancer Control AlbertaOTHER | 1 | Oct 2, 2025 | clinicaltrials |
| NCT06869213 | A Single-arm, Open, Single-center Exploratory Study of Adebrelimab (SHR-1316) in Combination With Chemotherapy for the Perioperative Treatment of Locally Advanced Resectable Esophageal Squamous Carcinoma | recruiting | Phase 2 | 30 | Peking University Cancer Hospital & InstituteOTHER | 1 | Oct 2, 2025 | clinicaltrials |
| NCT06869226 | A Multicenter Phase II Clinical Study of Neoadjuvant Use of Camrelizumab in Combination With Chemotherapy for Organ Preservation in Esophageal Cancer | recruiting | Phase 2 | 283 | Peking University Cancer Hospital & InstituteOTHER | 1 | Oct 2, 2025 | clinicaltrials |
| NCT07204574 | The Phase 1b/IIa, Open-label, Dose Escalation and Dose Expansion to Evaluate Safety, Tolerability, and Preliminary Efficacy of the Combination of HCB101, Cetuximab/Bevacizumab, and FOLFOX/FOLFIRI in Advanced or Metastatic Colorectal Cancer | recruiting | Phase 1 / Phase 2 | 40 | Chang Gung Memorial HospitalOTHER | 1 | Oct 2, 2025 | clinicaltrials |
| NCT07198165 | SCRT Followed by CAPOX + Bev ± PD-1 Inhibitor for TNT in LARC | recruiting | Phase 2 | 104 | Ruijin HospitalOTHER | 1 | Sep 30, 2025 | clinicaltrials |
| NCT06349317 | Neoadjuvant IMRT Combined With Camrelizumab and Apatinib for Resectable HCC With PVTT | recruiting | Phase 2 | 33 | Yongyi ZengOTHER | 1 | Sep 29, 2025 | clinicaltrials |
| NCT06467799 | Neoadjuvant HAIC and PD-1 Plus Adjuvant PD-1 for High-risk Recurrent HCC | recruiting | Phase 2 | 39 | Sun Yat-sen UniversityOTHER | 1 | Sep 29, 2025 | clinicaltrials |
| NCT06008054 | A Study of SI-B003, BL-B01D1+SI-B003 and BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Esophageal Cancer, Gastric Cancer, Colorectal Cancer and Other Gastrointestinal Tumors | recruiting | Phase 2 | 376 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 26, 2025 | clinicaltrials |
| NCT07194005 | Conversion Therapy With RC48, Sintilimab, and SOX for HER2 1+/2+ Unresectable Gastric Cancer(Remission) | recruiting | Phase 2 | 30 | Fudan UniversityOTHER | 1 | Sep 26, 2025 | clinicaltrials |
| NCT05116072 | Efficacy and Safety of TPIAT for Resectable Adenocarcinoma of the Pancreas Region at High Risk of Postoperative Fistula(TPIAT-01) | recruiting | Phase 1 / Phase 2 | 36 | University Hospital, LilleOTHER | 1 | Sep 25, 2025 | clinicaltrials |
| NCT07140679 | Immunotherapy (Toripalimab) for Reducing Recurrence Risk After Surgery for Mismatch Repair Deficient Stage IIB, IIC, or III Colon Cancer | recruiting | Phase 2 | 40 | Emory UniversityOTHER | 1 | Sep 25, 2025 | clinicaltrials |
| NCT07192185 | Systemic Chemotherapy With FOLFOX Plus Atezolizumab & Bevacizumab for Patients With Advanced HCC Who Previously Received Atezolizumab & Bevacizumab | recruiting | Phase 2 | 30 | Sun Yat-sen UniversityOTHER | 1 | Sep 25, 2025 | clinicaltrials |
| NCT06368141 | Neoadjuvant Chemotherapy Plus Sequential Immune Checkpoint Inhibitor (ICI) Therapy in Locally Advanced Colon Cancer(NeoCHIC) | recruiting | Phase 2 | 56 | Ruijin HospitalOTHER | 1 | Sep 24, 2025 | clinicaltrials |
| NCT05381038 | Optimizing and Personalising Azacitidine Combination Therapy for Treating Solid Tumours QPOP and CURATE.AI | recruiting | Phase 1 / Phase 2 | 10 | National University Hospital, SingaporeOTHER | 1 | Sep 23, 2025 | clinicaltrials |
| NCT06644937 | Single-arm Clinical Trial of TACE in Combination With Icaritin as Adjuvant Therapy After Surgery in Patients With Hepatocellular Carcinoma at High Risk of Recurrence | recruiting | Phase 2 / Phase 3 | 30 | Zhujiang HospitalOTHER | 1 | Sep 23, 2025 | clinicaltrials |
| NCT06770439 | IBI343 Combined With Chemotherapy in Advanced Pancreatic Cancer | recruiting | Phase 2 | 64 | Zhejiang UniversityOTHER | 1 | Sep 23, 2025 | clinicaltrials |
| NCT07188103 | Ivonescimab Plus Short-Course Hypofractionated Radiotherapy as Second-Line Therapy for Esophageal Squamous Cell Carcinoma | recruiting | Phase 2 | 37 | Anhui Provincial HospitalOTHER_GOV | 1 | Sep 23, 2025 | clinicaltrials |
| NCT07188441 | Treatment of Newly Diagnosed Central Malignant Germ Cell Tumor People With Teniposide Injection Combined With Cisplatin. | recruiting | Phase 2 | 40 | Chengcheng GuoOTHER | 1 | Sep 23, 2025 | clinicaltrials |
| NCT06253611 | First-line EXL01 With Nivolumab and FOLFOX for PD-L1 CPS ≥5 Metastatic Gastric Cancer(BIG) | recruiting | Phase 2 | 120 | GERCOR - Multidisciplinary Oncology Cooperative GroupOTHER | 1 | Sep 22, 2025 | clinicaltrials |
| NCT06767813 | Clinical Study of TQB2868 Injection Combined With Anlotinib Capsule and Chemotherapy in the First-line Treatment of Metastatic Pancreatic Neoplasms | recruiting | Phase 2 | 80 | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 19, 2025 | clinicaltrials |
| NCT06601309 | Biomarker Based Neoadjuvant Strategies for Locally Advanced Resectable ESCC(ESCC) | recruiting | Phase 2 | 90 | Fujian Medical University Union HospitalOTHER | 1 | Sep 15, 2025 | clinicaltrials |
| NCT06831136 | Endoscopic Ultrasound Radiofrequency Ablation and Immunotherapy Pembrolizumab for Locally Advanced Unresectable and Metastatic Pancreatic Duct Adenocarcinoma(PANCARDINAL-2) | recruiting | Phase 2 | 24 | The University of Texas Health Science Center, HoustonOTHER | 1 | Sep 10, 2025 | clinicaltrials |
| NCT06999694 | Proton Radiotherapy Plus Tremelimumab/Durvalumab for BCLC Stage B and C HCC(Proton-STRIDE) | recruiting | Phase 2 | 45 | Chang Gung Memorial HospitalOTHER | 1 | Sep 10, 2025 | clinicaltrials |
| NCT07102901 | Safety and Efficacy of SHR2554 Combined With Other Antitumor Therapies in Gastric or Gastro-oesophageal Junction Adenocarcinoma | recruiting | Phase 2 | 351 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Sep 10, 2025 | clinicaltrials |
| NCT07165847 | Neoadjuvant Radiotherapy Plus Tegafur, Oxaliplatin and Iparomlimab and Tuvonralimab in Resectable Gastric and GE-junction Cancer : A Randomized, Two-arm, Prospective Trial (TRIUNITE-05) | recruiting | Phase 2 | 40 | Daping Hospital and the Research Institute of Surgery of the Third Military Medical UniversityOTHER | 1 | Sep 10, 2025 | clinicaltrials |
| NCT06682793 | A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression(DENALI-1) | recruiting | Phase 1 / Phase 2 | 240 | A2 Biotherapeutics Inc.INDUSTRY | 1 | Sep 9, 2025 | clinicaltrials |
| NCT06770270 | Pucotenlimab Plus Radiotherapy and Chemotherapy for Neoadjuvant Treatment of Locally Advanced Rectal Cance(PUCRT)(PUCRT) | recruiting | Phase 2 | 68 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Sep 4, 2025 | clinicaltrials |
| NCT07154082 | Apatinib Mesylate and Camrelizumab Combined With TACE as Neoadjuvant Therapy for Hepatocellular Carcinoma | recruiting | Phase 2 | 27 | Wei ZhangOTHER | 1 | Sep 4, 2025 | clinicaltrials |
| NCT07154316 | Phase II RCT of LCRT vs SCRT + CAPOX/PD-1i/COX-2i in MSS Locally Advanced Rectal Cancer | recruiting | Phase 2 | 138 | Fudan UniversityOTHER | 1 | Sep 4, 2025 | clinicaltrials |
| NCT06902389 | A Clinical Study of Multi-target Hi-TCR-T Cells in the Treatment of Advanced Hepatocellular Carcinoma | recruiting | Phase 1 / Phase 2 | 30 | Eastern Hepatobiliary Surgery HospitalOTHER | 1 | Sep 3, 2025 | clinicaltrials |
| NCT07152678 | Brachytherapy With Radiotherapy and Immunotherapy: Guided HDR Trial in Esophageal Squamous Cell Carcinoma(BRIGHT-ESCC) | recruiting | Phase 2 | 60 | National Taiwan University HospitalOTHER | 1 | Sep 3, 2025 | clinicaltrials |
| NCT05706779 | Encorafenib Plus Cetuximab in a Neoadjuvant Setting in Patients With BRAF Mutation Localised Colon or Upper Rectum Cancer(NEORAF) | recruiting | Phase 2 | 30 | Federation Francophone de Cancerologie DigestiveOTHER | 1 | Sep 2, 2025 | clinicaltrials |
| NCT07150949 | Long-course Chemoradiotherapy or Short-course Radiotherapy Combined With CAPOX, PD-1antibody, and COX-2 Inhibitor for MSS Locally Advanced Rectal Cancer (SERRAC) | recruiting | Phase 2 | 138 | Fudan UniversityOTHER | 1 | Sep 2, 2025 | clinicaltrials |
| NCT06509568 | Neoadjuvant ChemoRadiotherapy Followed by Immunotherapy and Surgery for Resectable Esophageal Squamous Cell Carcinoma(CRIS-2 Trial) | recruiting | Phase 2 | 92 | Zhejiang Cancer HospitalOTHER | 1 | Aug 29, 2025 | clinicaltrials |
| NCT05576480 | SCRT Sequential Penpulimab in Combination With CAPEOX in the Neoadjuvant Treatment of MSS Locally Advanced Rectal Cancer(SPARC) | recruiting | Phase 2 | 55 | Ruijin HospitalOTHER | 1 | Aug 28, 2025 | clinicaltrials |
| NCT06887218 | 5-Fluorouracil/Leucovorin (5FU/LV) in Combination With Regorafenib in Patients With Metastatic Colorectal Cancer | recruiting | Phase 2 | 57 | The Methodist Hospital Research InstituteOTHER | 1 | Aug 27, 2025 | clinicaltrials |
| NCT07018661 | [18F]F-FAPI PET/CT and Laparoscopy in Staging Advanced Gastric Cancer(PLASTIC-3) | recruiting | Phase 2 / Phase 3 | 250 | Leiden University Medical CenterOTHER | 1 | Aug 27, 2025 | clinicaltrials |
| NCT07135544 | A Single-arm, Multicenter, Exploratory Study of Adebrelimab Combined With Apatinib and Systemic Chemotherapy for Initially Unresectable Biliary Tract Cancer | recruiting | Phase 2 | 37 | Yongjun ChenOTHER | 1 | Aug 22, 2025 | clinicaltrials |
| NCT06758544 | A Single-arm, Open-label Clinical Study to Evaluate the Efficacy and Safety of VRT106 in Combination With Chemotherapy for Resectable Pancreatic Cancer | recruiting | Phase 1 / Phase 2 | 18 | Guangdong Provincial People's HospitalOTHER | 1 | Aug 17, 2025 | clinicaltrials |
| NCT07100392 | Tauroursodeoxycholic Acid (TUDCA) Plus Camrelizumab and Regorafenib in Hepatocellular Carcinoma Previously Treated With Anti-PD1/PD-L1 and Bevacizumab(LEAF-02) | recruiting | Phase 2 | 141 | Fudan UniversityOTHER | 1 | Aug 17, 2025 | clinicaltrials |
| NCT07105748 | HAIC Combined With Camrelizumab Plus Rivoceranib for Advanced Mixed Hepatocellular-cholangiocarcinoma (HCC-CCA)(TASK-05) | recruiting | Phase 2 | 45 | Fudan UniversityOTHER | 1 | Aug 17, 2025 | clinicaltrials |
| NCT07123545 | Autologous Neoantigen-Specific T-Cell Therapy for Advanced Hepatocellular Carcinoma | recruiting | Phase 1 / Phase 2 | 20 | Zhejiang UniversityOTHER | 1 | Aug 14, 2025 | clinicaltrials |
| NCT07119463 | Effect of Goal-Oriented Albumin Infusion on Postoperative Complication Management in Gastric Cancer Surgery(GOAI) | recruiting | Phase 2 | 112 | The First Hospital of Jilin UniversityOTHER | 1 | Aug 13, 2025 | clinicaltrials |
| NCT06298916 | 64Cu-LNTH-1363S in Patients With Sarcoma or Gastrointestinal Tract Cancer(PHANTOM) | recruiting | Phase 1 / Phase 2 | 26 | Lantheus Medical ImagingINDUSTRY | 1 | Aug 12, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Nov 4, 2025source: clinicaltrials